Literature DB >> 10028979

Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial.

P M Schofield1, L D Sharples, N Caine, S Burns, S Tait, T Wistow, M Buxton, J Wallwork.   

Abstract

BACKGROUND: Transmyocardial laser revascularisation (TMLR) is used to treat patients with refractory angina due to severe coronary artery disease, not suitable for conventional revascularisation. We aimed in a randomised controlled trial to assess the effectiveness of TMLR compared with medical management.
METHODS: 188 patients with refractory angina were randomly assigned TMLR plus normal medication or medical management alone. At 3 months, 6 months, and 12 months after surgery (TMLR) or initial assessment (medical management) we assessed exercise capacity with the treadmill test and the 12 min walk.
FINDINGS: Mean treadmill exercise time, adjusted for baseline values, was 40 s (95% CI -15 to 94) longer in the TMLR group than in the medical-management group at 12 months (p=0.152). Mean 12 min walk distance was 33 m (-7 to 74) further in TMLR patients than medical-management patients (p=0.108) at 12 months. The differences were not significant or clinically important. Perioperative mortality was 5%. Survival at 12 months was 89% (83-96) in the TMLR group and 96% (92-100) in the medical-management group (p=0.14). Canadian Cardiovascular Society score for angina had decreased by at least two classes in 25% of TMLR and 4% of medical-management patients at 12 months (p<0.001).
INTERPRETATION: Our findings show that the adoption of TMLR cannot be advocated. Further research may be appropriate to assess any potential benefit for sicker patients.

Entities:  

Mesh:

Year:  1999        PMID: 10028979     DOI: 10.1016/s0140-6736(98)11478-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  29 in total

Review 1.  Neurostimulation treatment for angina pectoris.

Authors:  S Murray; P D Collins; M A James
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

2.  Laser to the heart in coronary artery disease.

Authors:  N Tamaki
Journal:  Int J Card Imaging       Date:  2000-08

3.  Percutaneous Myocardial Revascularization.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

4.  How well is the clinical importance of study results reported? An assessment of randomized controlled trials.

Authors:  K B Chan; M Man-Son-Hing; F J Molnar; A Laupacis
Journal:  CMAJ       Date:  2001-10-30       Impact factor: 8.262

Review 5.  Epicardial gene therapy and laser revascularization.

Authors:  J F Symes
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

Review 6.  Transmyocardial laser revascularization versus medical therapy for refractory angina.

Authors:  Eduardo Briones; Juan Ramon Lacalle; Ignacio Marin-Leon; José-Ramón Rueda
Journal:  Cochrane Database Syst Rev       Date:  2015-02-27

7.  The prospective clinical and scintigraphic assessment of patients with preserved left ventricular systolic function after transmyocardial laser revascularisation.

Authors:  Miroslaw A Dziuk; Ana Canizales; Nidhal Ali; Hany El-Deeb; Keith E Britton; Duncan S Dymond; Stephen J Edmondson
Journal:  Int J Cardiovasc Imaging       Date:  2005-08       Impact factor: 2.357

8.  Transmyocardial revascularization ameliorates ischemia by attenuating paradoxical catecholamine-induced vasoconstriction.

Authors:  D Elizabeth Le; Eric R Powers; Jian-Ping Bin; Howard Leong-Poi; N Craig Goodman; Sanjiv Kaul
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

Review 9.  Transmyocardial laser revascularization.

Authors:  Keith A Horvath
Journal:  J Card Surg       Date:  2008 May-Jun       Impact factor: 1.620

10.  Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions.

Authors:  Kimberley A Goldsmith; Matthew T Dyer; Peter M Schofield; Martin J Buxton; Linda D Sharples
Journal:  Health Qual Life Outcomes       Date:  2009-11-26       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.